PHARMACEUTICAL COMPANIES INDIA
Egypt to intensify India ties to counter extremist ideology: EAM Abdelatty
Egypt has taken a bold step in addressing the complexities of global terrorism by highlighting the Muslim Brotherhood’s implications. The country is dedicating resources to deradicalization initiatives focused on youth engagement and Imams' training. Furthermore, Egypt is advocating for a multinational stabilization force in Gaza through a UN resolution.
Roche Vs Natco: Supreme Court clears decks for launch of Natco Pharma's Risdiplam generic in India
The Supreme Court has allowed Natco Pharma to launch its generic version of the spinal muscular atrophy drug Risdiplam in India, dismissing F. Hoffmann-La Roche's appeal. The court upheld the Delhi High Court's decision, which prioritized public access to the life-saving medication at a significantly lower price.
Special teams formed to monitor drug firms in Tamil Nadu: Minister Subramanian
Tamil Nadu has formed special teams to continuously monitor its 397 pharmaceutical firms following infant deaths linked to a local company's cough syrup. Inspections have begun at 50 firms, with more planned, after a toxic substance was found in a banned syrup. Criminal proceedings and license revocation are underway.
Indian firms explore localisation of pharma production in Russia
The Russian market is attracting growing interest from Indian pharmaceutical companies exploring opportunities to establish production facilities across various regions of the country. This was announced by Moscow Government Minister and Head of the Department for External Economic and International Relations, Sergey Cheremin, during the " Russia-India. Mutual Efficiency" forum.
IT sector faces slower growth despite AI buzz; midcap firms better placed: Nitin Raheja
India is not yet participating in the global AI rally. Consumption is expected to remain a key growth driver. Financials are poised for an earnings revival, with private banks and select PSU banks offering attractive opportunities. Midcap IT companies may benefit from AI transitions. The market anticipates a supportive backdrop for growth.
India to force drugmakers to upgrade plants after fatal cough syrup crisis
India has denied drugmakers more time to upgrade manufacturing facilities. This decision follows the deaths of at least 24 children from contaminated cough syrup. The government mandated World Health Organization standards after similar incidents abroad. Despite pleas from smaller firms, officials are firm on the deadline.
- Go To Page 1
B.R. Shetty: How Indian entrepreneur went from Padma Shri honouree to losing his $10 billion healthcare empire
B.R. Shetty built a vast healthcare and finance empire from scratch in the UAE. His ventures, including NMC Health and UAE Exchange, achieved global recognition. However, the empire faced a dramatic collapse in 2020 due to undisclosed debt and financial irregularities. Shetty is now involved in ongoing legal battles as his once-billion-dollar empire has largely dissolved.
Alchem International moves Delhi HC against single-judge order on ‘Alchem’ trademark
Alchem International is challenging a court order that stops it from using its name. The order prevents Alchem from selling products with the name 'Alchem' due to similarity with Alkem Laboratories' trademark. A division bench is reviewing the case. The court previously found the names phonetically identical. Alkem has used its trademark since 1973. Alchem started using its mark later.
Nomura sets Nifty50 target at 26,140 for March 2026, adds 3 stocks to preferred list
Nomura maintains its Nifty50 target at 26,140 for March 2026, adding Prestige Estates, Swiggy, and Titan to its preferred stocks list. The brokerage favours sectors like Financials, Autos, Cement, and Pharmaceuticals while remaining cautious on Capital Goods, IT Services, and Metals amid modest recovery expectations.
Healthy start! Rubicon Research shares list at 28% premium over IPO price
Rubicon Research Share Price debuted on stock exchanges with a significant 27.9% premium, opening at Rs 620. The Rs 1,377 crore IPO saw overwhelming demand, subscribed 109 times, driven by strong QIB interest. Analysts cite robust financials, a specialized US generics portfolio, and a scalable model for the excitement.
Graph AI raises $3 million seed funding for drug safety platform
AI life sciences startup Graph AI has secured $3 million in seed funding to revolutionise pharmacovigilance. The California-based startup leverages AI-driven automation to address the inefficiencies and errors in traditional drug safety monitoring. This funding will accelerate product innovation and global market expansion for their SaaS platform.
Torrent Pharma plans Rs 14,000 crore bond sale for JB Chemicals acquisition
Torrent Pharmaceuticals is planning a ₹14,000-crore bond sale to finance its acquisition of JB Chemicals & Pharmaceuticals. The company is in discussions with major banks for the funding package, which will be repaid through internal accruals. The proposed merger is awaiting regulatory approvals.
Prasol Chemicals files papers with Sebi to mobilise Rs 500-cr via IPO
Specialty chemicals manufacturer Prasol Chemicals has filed preliminary papers with capital markets regulator Sebi to raise Rs 500 crore through an initial public offering (IPO).
CDSCO seeks views on level playing field for new drugs
In a significant shift for the pharmaceutical market, India's drug regulator is crafting new legislation regarding drug approvals. Under this proposal, the first entity to introduce a novel drug will be mandated to perform clinical trials, while subsequent entrants will be allowed to forego these tests.
Roche moves SC against Natco’s launch of generic Risdiplam in India
F. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a generic version of Risdiplam. Risdiplam treats spinal muscular atrophy. The High Court rejected Roche's plea to halt Natco's manufacturing. Natco plans to sell the drug at a significantly lower price.
With the tariff threat headache over, time to focus on them again? 8 pharma stocks with upside potential of up to 39%
With a clear indication that no additional or special tariff will be imposed by the US on generic drugs, there is a sense of relief among Indian drug companies. The US healthcare system, too, must be relieved, given that India is the biggest supplier of generic drugs to the American market. Any increase in the cost of these medicines would have led to a disruption in the US healthcare system. Now that the tariff threat – which has been troubling Indian companies for the past year – is seemingly a thing of the past, will things get better on the street for Indian pharma companies?
Cough Syrup deaths: Sresan Pharmaceuticals' license cancelled, company shut down
Tamil Nadu has cancelled the manufacturing license of Sresan Pharmaceutical, maker of Coldrif cough syrup, after it was linked to at least 22 deaths in Madhya Pradesh due to toxic contaminants. The state ordered comprehensive inspections of all pharmaceutical units following the incident and the arrest of the company owner.
ED raids seven Chennai sites linked to Sresan Pharma over Coldrif cough syrup deaths
The Enforcement Directorate (ED) conducted searches at seven locations in Chennai concerning the Coldrif cough syrup case. These raids, under the PMLA, are linked to Sresan Pharma, the manufacturer of the banned syrup. The cough syrup has been linked to the deaths of approximately 22 children, primarily in Madhya Pradesh and Rajasthan.
Rubicon Research IPO Day 3: GMP, subscription status, brokerage views, and key highlights
Rubicon Research’s IPO, backed by Arihant Capital with a “Subscribe” rating, highlights the company’s strong growth and diversified pharma portfolio. The US-focused generics and specialty drug player has seen revenue jump to Rs 12,962 crore in FY25 and net profit rebound to Rs 1,344 crore. The IPO is fairly valued, aiming to attract both institutional and retail investors.
Sound businesses are the best antidote for volatility: 6 large- and mid-cap stocks with an upside potential of up to 30%
The market hates uncertainty. Post the big reforms (GST and banking), the markets should have ideally been in upbeat mode this festive season. But the US tariffs are a downer. And while the street is clearly hoping that an India-US trade pact will be inked soon, no deal is done till it is actually done. And given that the tariffs impact many sectors, the bears are lurking around just in case Trump puts a spanner in the works and everything goes south. As an investor, there is no point trying to guess what will happen. Focus, instead, on good businesses with an assured market and sound management. That will pay off in the long term.
Natco Pharma to acquire significant stake in S African firm Adcock Ingram
Indian pharmaceutical company Natco Pharma is set to acquire significant stakes in South Africa's Adcock Ingram, a 135-year-old firm, in a R4.2 billion deal. This acquisition will make Adcock Ingram a privately-held entity, co-owned by Natco and Bidvest, with Adcock Ingram delisting from the JSE post-completion.
As bulls make a comeback, stay with stocks that are best in their class: 5 large-caps with an upside potential of up to 33%
Here’s a question. Which of the following companies is better to invest in at a time of high valuations? First: A wealth-creator that has been around for over two decades; an industry leader with a management that has dealt with many economic slowdowns and has still emerged a winner. Second: A company that issued its IPO in the last few years; whose valuations are high because it is currently the flavour of the street. And whose management has no experience of dealing with downturns. The answer: Obviously, the first. The reality, however, is that most investors ignore the first lot and go for companies that make headlines and a lot of noise, quite forgetting the basics of investing.
Rubicon Research IPO Day 2: Issue booked 2.37 times. Check GMP, other details
Rubicon Research's IPO saw strong investor demand, subscribed 2.37 times. The pharma firm specializes in generics and specialty drugs. Its financial performance shows a significant turnaround. Analysts are positive about its growth and international market presence. The company operates in the US, Canada, and India. Its IPO is expected to attract both institutional and retail investors.
Tariff pause eases pressure on drug companies
Indian drug makers can breathe easier as the US reportedly shelves plans for tariffs on generic drug imports. This move is a significant relief for Indian pharmaceutical companies, which supply nearly half of all generic prescriptions in the United States. Experts believe the US recognized the potential for price hikes and drug shortages for its own citizens.
Rubicon Research IPO Day 1: Subscribed 51% in initial hours – Check GMP, Brokerages' views, and key details
Rubicon Research IPO: Rubicon Research is trading at a grey market premium of ₹90, roughly 19% above the upper price band, reflecting strong listing expectations driven by investor interest in the healthcare and pharmaceutical sector.
'Our govt will not spare the accused,' says MP CM Mohan Yadav on arrest of Sresan Pharma Owner
Madhya Pradesh Chief Minister Mohan Yadav has vowed strict action against all accused in the Chhindwara cough syrup deaths. The owner of Tamil Nadu-based Sresan Pharmaceuticals, manufacturer of the implicated Coldrif cough syrup, has been arrested. The state government is actively investigating and ensuring such incidents are prevented in the future.
Trump & Co said to have shelved generic drug tariffs, Indian pharma stocks get booster dose
The Trump White House has halted plans for tariffs on generic drug imports, a decision welcomed by Indian pharma companies that supply nearly half of US generic prescriptions. This move reassures millions of Americans relying on affordable imported medications for various health conditions, averting potential price hikes and shortages.
India declares three cough syrups toxic after child deaths
India has declared three cough syrups toxic. Seventeen children have died in the past month. All deaths are linked to Coldrif. Regulators also advise avoiding Respifresh TR and ReLife. None of the syrups were exported. The World Health Organization warned of risks through unregulated channels. Coldrif contained high levels of diethylene glycol. The owner of Sresan Pharmaceutical Manufacturer was arrested.
Rubicon Research IPO: Check GMP, brokerages review, subscription and other details
Rubicon Research's Rs 1,377 crore IPO opens on October 9. The specialty and generics pharmaceutical manufacturer offers shares at Rs 461-485. Grey market premium indicates strong listing expectations. Arihant Capital recommends subscribing due to growth and product pipeline. The company shows a financial turnaround with surging revenue and profit. This IPO offers exposure to a fast-scaling pharma exporter.
Load More
